1、Product Data SheetElacridarCat. No.: HY-50879CAS No.: 143664-11-3分式: CHNO分量: 563.64作靶點: BCRP; P-glycoprotein作通路: Membrane Transporter/Ion Channel儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 5 mg/mL (8.87 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)Solvent

2、Mass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 1.7742 mL 8.8709 mL 17.7418 mL5 mM 0.3548 mL 1.7742 mL 3.5484 mL10 mM - - -請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲存時，請在 1 個內使。體內實驗請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的

3、儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據儲存條件，適當保存；體內實驗的作液，建議您現現配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.5 mg/mL (0.89 mM); Clear solution此案可獲得 0.5 mg/mL (0.89 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 5.0 mg/mL 的澄 DM

4、SO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 0.5 mg/mL (0.89 mM); Precipitated solution; Need ultrasonicPage 1 of 2 www.MedChemE此案可獲得 0.5 mg/mL (0.89 mM)以 1 mL 作液為例，取 100 L 5.0 mg/mL 的澄DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL

5、ACTIVITY物活性 Elacridar種有效的 P-糖蛋 (P-glycoprotein) 和 BCRP 的抑制劑。IC & Target P-glycoprotein (Pgp), BCRP1體外研究 Elacridar inhibits P-glycoprotein (P-gp) labeling by 3Hazidopine with a IC50 of 0.16 M2. In Caki-1 and ACHN cells,elacridar (2.5 M) significantly ihibits the cell growth. The P-glycoprotein activi

6、ty is found to be inhibited by elacridar.The combination of elacridar and sunitinib lead to a significant reduction in ABC Sub-family B Member 2 (ABCG2)expression in 786-O cells3.體內研究 Oral co-administration of elacridar (100 mg/kg, p.o.) and crizotinib increases the plasma and brain concentrations a

7、ndbrain-to-plasma ratios of crizotinib in wild-type mice, equaling the levels in Abcb1a/1b; Abcg2-/- mice1. In friendleukemia virus stain B mice, the brain-to-plasm partition coefficient (Kp, brain) of elacridar is 0.82, 0.43, and 4.31 afterintravenous (2.5 mg/kg), intraperitoneal (100 mg/kg), and o

8、ral (100 mg/kg) treatment, respectively4. In Mrp4(-/-)mice, elacridar fully inhibits P-gp mediated transport of topotecan, without siginificant effects on Bcrp1-mediatedtransport5.PROTOCOLKinase Assay 2 10 L of unlabeled cell membrane suspension (at 0.4 mg of protein/mL) are aliquoted into each well

9、 in 96-well plates.5 L of GF120918 are then added to each well. The plate is incubated 25 min at 25C in the dark. 5 L of tritiatedazidopine (1.8 TBq/mmol) (0.6 M in HCI 0.2 mM) are added to each well. After 25 min of incubation at 25C in thedark, samples are simultaneously irradiated for 2 min at 25

10、4 nm at 0C with a thin layer chromatography-designedUV lamp directly in contact with the plate. Samples are solubilized in sodium dodecyl sulfate-polyacrylamide gelelectrophoresis sample buffer but not heated. After separation on a 7.5% polyacrylamide gel, the gel is treated forfluorography with Amp

11、lify and exposed during 3 days onto a photosensitive film. The fluorography is analysed usinga Camag thin layer chromatography Scanner II densitometer.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 3 3.0103 cells per well are seeded in a 96-

12、well plate. After 24 h incubation, an optimum concentration gradient ofelacridar is added to each well. After culturing for 48 h, cell viability is assessed using the proliferation reagent, MTT.Control cells are treated with the vehicle only, 0.1% DMSO. After this final incubation, the medium is asp

13、irated andprecipitated formazan crystals are dissolved in DMSO (100 L/well). The absorbance of each well is measured at 540nm, and a reference wavelength of 650 nm is read with a multiskan JX microplate reader. Cell viability is calculated aspercentage of the control value3.MCE has not independently

14、 confirmed the accuracy of these methods. They are for reference only.Animal Mice are fasted for 3 hr before oral administration of either elacridar (100 mg/kg) or elacridar vehicle. Two hoursAdministration 1 later, crizotinib (5 mg/kg) is administered to mice orally. Blood and brains are isolated 4

15、 hr after crizotinib oraladministration, and processed as described above. The brain concentrations are corrected for the amount of drug inthe brain vasculature. Elacridar hydrochloride is dissolved in dimethyl sulfoxide (106 mg/mL) in order to get 100 mgpure elacridar per 1 mL of dimethyl sulfoxide

16、. The stock solution is further diluted with a mixture of Polysorbate 80,ethanol and water 20:13:67 (v/v/v) to yield a concentration of 10 mg/mL pure elacridar.Page 2 of 3 www.MedChemEMCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發表的科研獻 Clin Canc

17、er Res. 2018 Jan 15;24(2):383-394. Cell Death Dis. 2019 May 24;10(6):400. J. Mater. Chem. B. 2018 Oct. Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. J Agric Food Chem. 2019 Feb 27;67(8):2350-2360.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Tang SC, et al. Increase

18、d oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) andbreast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-942. Hyafil F, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993 Oct 1;53(19):4595-602.3. Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2